Expression of e-cadherin in high-risk breast cancer

Howard, Eugene M.; Lau, Stephen K.; Lyles, Robert H.; Birdsong, George G.; Umbreit, Jay N.; Kochhar, Ruby

doi:10.1007/s00432-004-0618-z

Cited by 24 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human breast cancer, conflicting results are also to be found in the literature. Thus, significant differences were reported by some authors (Siitonen et al, 1996;Charpin et al, 1997;Gonzalez et al, 1999;Parker et al, 2001;Cobanoglu et al, 2004) but not by others (Jones et al, 1996;Kovacs et al, 2003;Howard et al, 2005). Gamallo et al (1993) demonstrated greater immunoreactivity in grade I carcinomas than in grade II and grade III, giving support to our results.…”

Section: Discussionsupporting

confidence: 83%

“…This contrasted with some studies in human breast cancer in which either no such association was demonstrated (Charpin et al, 1997;Parker et al, 2001;Kovacs et al, 2003;Cobanoglu et al, 2004) or increased E-cadherin immunolabelling was observed as tumour size increased (Howard et al, 2005). Heimann et al (2000), however, concluded that in breast cancer there was a trend towards decreased E-cadherin expression with increased tumour size.…”

Section: Discussionmentioning

confidence: 73%

“…In human breast cancer a significant association between the presence of E-cadherin expression and absence of lymph node metastasis was reported in some (Jones et al, 1996;Hunt et al, 1997;Zschiesche et al, 1997;Madhavan et al, 2001) but not in other studies (Charpin et al, 1997;Burkholm et al, 1998;Gonzalez et al, 1999;Parker et al, 2001;Kovacs et al, 2003). In three studies of human breast cancer, however, it was found that high E-cadherin expression was associated with a larger number of lymph nodes considered positive for metastasis (Siitonen et al, 1996;Gillett et al, 2001;Howard et al, 2005). Extended studies, for instance on matrix composition, will be needed to gain insight into the fine-tuning of E-cadherin functions by the tumour microenvironment.…”

Section: Discussionmentioning

confidence: 96%

See 2 more Smart Citations

E-cadherin Expression in Canine Malignant Mammary Tumours: Relationship to Other Clinico-Pathological Variables

Matos

Lopes

Carvalheira

et al. 2006

Journal of Comparative Pathology

View full text Add to dashboard Cite

SummaryThe relationship between E-cadherin epithelial expression, as detected by immunohistochemical methods, and other clinico-pathological characteristics of canine malignant mammary tumours was studied in 77 tumours surgically removed from 45 female dogs. The immunohistochemical assessment was based on the estimated percentage of epithelial cells with membranous labelling. Reduction of E-cadherin expression was significantly related to size and ulceration of tumours but not to fixation to skin or underlying tissue; it was also related to lymph node metastasis, necrosis and infiltrative growth. Histological type (but not histological grade) was related to E-cadherin expression, with solid tumours more frequently lacking expression and tubulopapillary tumours showing increased expression as compared with the other types. The significant relationship between E-cadherin and other known factors of poor prognosis suggests that the loss of E-cadherin expression may have prognostic value in canine malignant mammary tumours. q

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

E-cadherin Expression in Canine Malignant Mammary Tumours: Relationship to Other Clinico-Pathological Variables

Matos

Lopes

Carvalheira

et al. 2006

Journal of Comparative Pathology

View full text Add to dashboard Cite

show abstract

“…The remaining 26 did not meet inclusion criteria. Eighteen were excluded for study design: 11 were case series [11,[22][23][24][25][26][27][28][29][30][31], two were case-control studies [32,33] and five were cross-sectional analyses [13-15, 34, 35]. Four studies did not report on 5-year all-cause or breast cancer-specific mortality [5,10,36,37].…”

Section: Methodologic Assessmentmentioning

confidence: 99%

E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis

Rothberg

Bracken

2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

Loss of E-cadherin expression may be an independent negative prognostic indicator for infiltrating ductal breast carcinoma and randomized, controlled studies evaluating this finding are justified. We encourage standardization of immunohistochemical techniques, data interpretation algorithms across laboratories and use of all-cause mortality to increase data compatibility and facilitate future efforts summarizing the utility of alternate prognostic markers in cancer.

show abstract

“…Claudin-3 and -4 are expressed at higher level in high-grade and ER- tumors, especially in BLBC [31,33]. Claudin-4, in line with E-cadherin, was found to be a biomarker predicting poor prognosis in BC [34,35]. At mRNA (derived from in silico data) and protein expression (derived from our IHC investigations) level, we have noted a discrepancy, which we suggest is the result of the following: (i) the sample number was still low, although we used all available public gene expression data sets and all available BRCAmut and BRCAwt cases from both our archives; (ii) correspondingly, the FFPE cohort could not be matched for age and hormone receptor/subtype status to the data set analyzed by bioinformatics, and (iii) epigenetic regulation may alter the translation process of the proteins investigated.…”

Section: Discussionmentioning

confidence: 99%

BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?

et al. 2015

View full text Add to dashboard Cite

Background: BRCA mutation-associated (BRCAmut) breast cancer represents a heterogeneous group displaying certain molecular features. Claudin-low breast cancers (CLBC) overlap with characteristics of BRCAmut tumors; therefore, we have investigated whether these are identical subtypes. Methods: Using public gene expression data, CLDN, CDH1, 9-cell line claudin-low predictor (9CLCLP) and PAM50 expression was evaluated in BRCAmut and BRCA wild-type (BRCAwt) breast cancer cases focusing on their possible overlap with the CLBC subtype. A separate formalin-fixed, paraffin-embedded (FFPE) cohort of 22 BRCAmut and 19 BRCAwt tumor tissues was used for immunohistochemical examination of AR, CD24, CD44, CK5/6, claudin-1, -3, -4 and -7, E-cadherin, EGFR, estrogen receptor (ER), EZH2, HER2, Ki67, p53, progesterone receptor (PgR) and vimentin expression. Results: In the data sets, CLDN1 (ROC = 0.785, p < 0.001), CDH1 (ROC = 0.785, p < 0.001), CLDN7 (ROC = 0.723, p < 0.001), CLDN3 (ROC = 0.696, p = 0.020) and CLDN4 (ROC = 0.685, p = 0.027) were expressed at higher level in BRCAmut than BRCAwt tumor tissue. The PAM50 subtype differed from the assigned immunohistochemistry (IHC)-based subtype in 30%. Based on accessible 9CLCLP predictor genes, BRCAmut breast cancer does not display the claudin-low phenotype. Utilizing FFPE samples, claudins were evidently expressed in both BRCAmut and BRCAwt cases. However, at the protein level, only claudin-3 expression was higher in BRCAmut tumors, while claudin-1, -4 and -7 and E-cadherin expression was lower compared to BRCAwt cases. A CD24^low/CD44^high phenotype was found in BRCAmut tumors upon comparison with BRCAwt cases (p < 0.001 and p = 0.001, respectively). Conclusions: There is a prominent correlation between the genes under focus herein and BRCA mutation status. BRCAmut tumors bear stem cell characteristics displaying a distinct cell adhesion molecule profile characterized by high expression of CDH1 and CLDN4 according to public gene expression data set analysis, and higher claudin-3 expression as detected by IHC; thus, BRCAmut breast carcinomas are not identical with the previously identified claudin-low subtype of breast cancer.

show abstract

Expression of e-cadherin in high-risk breast cancer

Abstract: In contrast to other studies on heterogeneous populations, e-cadherin is preserved in aggressive tumors in this high-risk population. The ethnic and socio-economic risk stratification needs to be accounted for in studies correlating markers and prognosis.

Cited by 24 publications

References 18 publications

E-cadherin Expression in Canine Malignant Mammary Tumours: Relationship to Other Clinico-Pathological Variables

E-cadherin Expression in Canine Malignant Mammary Tumours: Relationship to Other Clinico-Pathological Variables

E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis

BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?

Contact Info

Product

Resources

About